News

Relizorb, Alcresta Therapeutics‘ pancreatic enzyme treatment, led to significant weight and height improvements among cystic fibrosis (CF) patients with pancreatic insufficiency who require tube feeding, according to the results of a 12-month observational study. The analysis of that study, “Evaluation of the Effectiveness…

Following yearlong advocacy efforts, the triple-combination therapy Trikafta is expected to soon come up for approval before Health Canada, the country’s health regulatory agency, the non-profit patient group Cystic Fibrosis Canada has announced on its website. Vertex Pharmaceuticals, which developed and markets Trikafta, its newest modulator therapy for cystic fibrosis and…

New findings from animal studies support the safety and effectiveness of KB407, a potential inhaled gene therapy for cystic fibrosis, its developer, Krystal Biotech, announced. Preclinical work is ongoing, and the therapy is expected to enter clinical testing in patients by mid-2021. “I am particularly encouraged by progress with KB407 for…

Patient enrollment and dosing has resumed in a Phase 1/2 clinical trial testing MRT5005, Translate Bio‘s potential messenger RNA (mRNA) therapy for people with cystic fibrosis (CF) regardless of their underlying mutation. The trial, called RESTORE-CF trial (NCT03375047) and enrolling up to 40 adults with stable disease at 17 centers…

The NuvoAir Home platform — NuvoAir’s respiratory support system for people with lung diseases — allows adults and children with cystic fibrosis (CF) to gather high quality data on the health of their lungs at home and without medical supervision. Adherence to NuvoAir’s respiratory system, and its…

The Cystic Fibrosis Foundation (CFF) has awarded up to $2.4 million to Calithera Biosciences to advance in testing CB-280, its investigative oral therapy that aiming to lower the risk of lung infections in people with cystic fibrosis (CF). An enrolling clinical trial is underway in…

The European Commission has approved Kalydeco (ivacaftor), by Vertex Pharmaceuticals, to treat infants as young as four months old with cystic fibrosis (CF) caused by certain mutations. The decision to extend Kalydeco’s label to younger babies, weighing at least 5 kg (about 11 lbs) and with relevant mutations, follows…

The Cystic Fibrosis Foundation (CFF) has awarded funding to enGene to support its work on a non-viral and inhalable gene therapy that could deliver a working copy of the CFTR gene to the lungs of people with cystic fibrosis (CF). “Today’s announcement reflects yet another milestone on our path…

The U.S. Food and Drug Administration (FDA) has approved the dry inhalation powder Bronchitol (mannitol) as a maintenance treatment to be used along with other therapies for improving lung function in adults with cystic fibrosis (CF). Bronchitol is currently approved and marketed in Switzerland, Australia, Italy,…

Pseudomonas aeruginosa mutate into a mucoid form in the lungs of people with cystic fibrosis (CF), creating biofilms that render these bacteria more resistant and more damaging, a study reported. Its researchers suggest a way of studying P. aeruginosa cells to identify treatments…